UDZIAŁ KOMÓREK IMMUNOLOGICZNYCH W PATOGENEZIE ORBITOPATII GRAVESA

Anna Król

doi:10.56782/pps.30

Published : 2019-08-07

Vol. 17 No. 3 (2019)

THE ROLE OF IMMUNE CELLS IN THE PATHOGENESIS OF GRAVES' ORBITOPATHY

Anna Król

DOI: https://doi.org/10.56782/pps.30

Abstract

Graves’ disease (GD) is an autoimmune disorder causing overproduction of thyroid hormones and consequently metabolic dysfunctions. Graves’ orbitopathy (GO) is the main extrathyroidal manifestation of GD. It involves inflammation and swelling of the extraocular muscles and an increase in orbital fat and connective tissue. Extensive analyses of tissue samples obtained from patients with GO indicated the role of orbital fibroblasts, T lymphocytes as well as thyrotropin and insulin–like growth factor–1 receptors in development of this disease. The inflammatory infiltration and accumulation of glycosaminoglycans leads to the development of swelling and fibrosis of periocular tissues. Despite a progress in understanding of this pathomechanism, GO still remains one of the most difficult problems of clinical endocrinology. In this paper, studies related to the immunological mechanism of GO pathogenesis and the role of immune cells in the pathogenesis of the disease have been discussed.

Keywords:

Graves’ orbitopathy, inflammation, orbital fibroblasts, thyroid stimulating hormone receptor (TSHR)

Similar Articles

Małgorzata Krzyżanowska, Katarzyna Kozon, Jakub Olszewski, Andrzej Patyra, Efficacy of satralizumab therapy in the treatment of NMOSD , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)
Dominika Łacheta, Wioletta Olejarz, OCHRONNA ROLA KWASU α-LIPONOWEGO W MIAŻDŻYCY I CHOROBACH SERCOWO-NACZYNIOWYCH , Prospects in Pharmaceutical Sciences: Vol. 17 No. 8 (2019)
Anna Szymanowska, Agnieszka Gornowicz, Anna Bielawska, Krzysztof Bielawski, PLANT STEM CELLS AND THEIR APPLICATION IN COSMETOLOGY AND REGENERATIVE MEDICINE , Prospects in Pharmaceutical Sciences: Vol. 17 No. 7 (2019)
Maciej Bara, Jakub Starownik, Jakub Szydło, Patryk Gryszkiewicz, Jakub Nieznański, Dapagliflozin - new solution in chronic kidney disease treatment , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
Karolina Nowakowska, EPIDEMIOLOGY, CLASSIFICATION AND DIAGNOSIS OF FUNCTIONING AND NONFUNCTIONING PITUITARY ADENOMAS , Prospects in Pharmaceutical Sciences: Vol. 13 No. 6 (2015)
Martyna Chechłacz, Natalia Korytowska, COMPOUNDS THAT BIND TO PLASMA PROTEINS IN HUMANS. SIGNIFICANCE IN THERAPY AND METHODS FOR QUANTIFICATION OF A FREE FRACTION , Prospects in Pharmaceutical Sciences: Vol. 15 No. 6 (2017)
Patrycja Słomczyńska, Jakub Młoźniak, Katarzyna Paradowska, Over-the-counter antihistamines in insomnia therapy , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
Ewelina Flegiel, Magdalena Piotrowska, Magdalena Ptasznik, Aleksandra Baran, Justyna Lenart, Miłosz Podrażka, Joanna Mazurek, Hubert Stachowicz, Weronika Bartos, Monika Adamczyk, Review of the effects of sodium butyrate on obesity, inflammatory bowel disease, pregnancy and colorectal cancer , Prospects in Pharmaceutical Sciences: Vol. 22 No. 4 (2024)
Bartłomiej Pyrak, Karolina Rogacka, Dariusz Maciej Pisklak, Anti-leukotriene drugs in the therapy of inflammatory diseases , Prospects in Pharmaceutical Sciences: Vol. 20 No. 2 (2022)

<< < 1 2

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Król, A. (2019). THE ROLE OF IMMUNE CELLS IN THE PATHOGENESIS OF GRAVES’ ORBITOPATHY. Prospects in Pharmaceutical Sciences, 17(3), 14–19. https://doi.org/10.56782/pps.30

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Winsz-Szczotka K., Komosińska-Vassev K., Olczyk K., Metabolizm glikozoaminoglikanów w przebiegu choroby Gravesa-Basedowa The metabolism of glycosaminoglycans in the course of Graves’ disease, Postepy Hig Med Dosw, 2006, 60, 184-191.

De Leo S., Lee S. Y., Braverman L. E., Hyperthyroidism, Lancet, 2016, 388(10047), 906-918. DOI: https://doi.org/10.1016/S0140-6736(16)00278-6

Shimojo N., Kohno Y., Yamaguchi K., Kikuoka S., Hoshioka A., Niimi H., Hirai A., Tamura Y., Saito Y., Kohn L. D., Tahara K., Induction of Graves-like disease in mice by immunization with fibroblasts transfected with the thyrotropin receptor and a class II molecule, Proc Natl Acad Sci U S A, 1996, 93(20), 11074-11079. DOI: https://doi.org/10.1073/pnas.93.20.11074

Carvalho G. A., Perez C. L., Ward L. S., The clinical use of thyroid function tests, Arq Bras Endocrinol Metabol, 2013, 57(3), 193-204. DOI: https://doi.org/10.1590/S0004-27302013000300005

Prabhakar B. S., Bahn R. S., Smith T. J., Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy, Endocr Rev, 2003, 24(6), 802-835. DOI: https://doi.org/10.1210/er.2002-0020

Ji D. Y., Park S. H., Park S. J., Kim K. H., Ku C. R., Shin D. Y., Yoon J. S., Lee D. Y., Lee E. J., Comparative assessment of Graves’ disease and main extrathyroidal manifestation, Graves’ ophthalmopathy, by non-targeted metabolite profiling of blood and orbital tissue, Sci rep, 2018, 8(1), 9262. DOI: https://doi.org/10.1038/s41598-018-27600-0

Bahn R. S., Understanding the immunology of Graves' ophthalmopathy: Is it an Autoimmune Disease?, Endocrinol Metab Clin North Am, 2000, 29(2), 287-296. DOI: https://doi.org/10.1016/S0889-8529(05)70132-8

Miskiewicz P., Rutkowska B., Jablonska A., Krzeski A., TrautsoltJeziorska K., Kecik D., Milczarek-Banach J., Pirko-Kotela K., Samsel A., Bednarczuk T., Complete recovery of visual acuity as the main goal of treatment in patients with dysthyroid optic neuropathy, Endokrynol Pol, 2016, 67(2), 166-173. DOI: https://doi.org/10.5603/EP.a2016.0018

Khong J. J., McNab A. A., Ebeling P. R., Craig J. E., Selva D., Pathogenesis of thyroid eye disease: review and update on molecular mechanisms, Br J Ophthalmol, 2016, 100(1), 142-150. DOI: https://doi.org/10.1136/bjophthalmol-2015-307399

Bartalena L., Tanda M. L., Graves' ophthalmopathy, N Engl J Med, 2009, 360(10), 994-1001. DOI: https://doi.org/10.1056/NEJMcp0806317

Bartley G. B., The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota, Trans Am Ophthalmol Soc, 1994, 92, 477.

Shah Y., Thyroid ophthalmopathy, Suppl JAPI, 2011, 59, 60-65.

Janusz P., Pawlak-Adamska E., Kochanowska I. E., Daroszewski J., Udział tkanki tłuszczowej w patogenezie i obrazie klinicznym orbitopatii tarczycowej, Postepy Hig Med Dosw, 2013, 67. DOI: https://doi.org/10.5604/17322693.1078402

Bartalena L., Baldeschi L., Dickinson A. J., Eckstein A., KendallTaylor P., Marcocci C., Mourits M. P., Perros P., Boboridis K., Boschi A., Curro N., Daumerie C., Kahaly G. J., Krassas G., Lane C. M., Lazarus J. H., Marino M., Nardi M., Neoh C., Orgiazzi J., Pearce S., Pinchera A., Pitz S., Salvi M., Sivelli P., Stahl M., von Arx G., Wiersinga W. M., Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy, Thyroid, 2008, 18(3), 333-346. DOI: https://doi.org/10.1089/thy.2007.0315

Bahn R., Current insights into the pathogenesis of Graves’ ophthalmopathy, Horm Metab Res, 2015, 47(10), 773-778. DOI: https://doi.org/10.1055/s-0035-1555762

Lazarus J. H., Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease, Best Pract Res Clin Endocrinol Metab, 2012, 26(3), 273-279. DOI: https://doi.org/10.1016/j.beem.2011.10.005

Bednarczuk T., Bar-Andziak E., Hubalewska-Dydejczyk A., Waligórska A., Górska M., Myśliwiec J., Jarząb B., Karczmarzyk R., Zawadzka A., Garmol D., Kęcik D., Krolicki L., Płazińska M., Krzeski A., Krzyżanowska-Świniarska B., Lewiński A., Milewicz A., Daroszewski J., Placzkiewicz-Jankowska E., Nauman J., Postępowanie w orbitopatii towarzyszącej chorobie Gravesa i Basedowa. Komentarz i uzupełnienie do stanowiska EUGOGO, Endokrynol Pol., 2009, 60(4), 312-330.

Hiromatsu Y., Eguchi H., Tani J., Kasaoka M., Teshima Y., Graves' ophthalmopathy: epidemiology and natural history, Intern Med, 2014, 53(5), 353-360. DOI: https://doi.org/10.2169/internalmedicine.53.1518

Siomkajło M., Dybko J., Daroszewski J., Limfocyty regulatorowe w orbitopatii tarczycowej i autoimmunologicznych chorobach tarczycy, Postepy Hig Med Dosw, 2016, 70.

Pawlowski P., Reszec J., Eckstein A., Johnson K., Grzybowski A., Chyczewski L., Mysliwiec J., Markers of inflammation and fibrosis in the orbital fat/connective tissue of patients with Graves’ orbitopathy: clinical implications, Mediators Inflamm, 2014, 2014. DOI: https://doi.org/10.1155/2014/412158

Niedźwiedzka-Rystwej P., Tokarz-Deptuła B., Deptuła W., Charakterystyka subpopulacji limfocytów T, Postepy Hig Med Dosw, 2013, 67, 371-379. DOI: https://doi.org/10.5604/17322693.1048814

Mao C., Wang S., Xiao Y., Xu J., Jiang Q., Jin M., Jiang X., Guo H., Ning G., Zhang Y., Impairment of Regulatory Capacity of CD4+CD25+ Regulatory T Cells Mediated by Dendritic Cell Polarization and Hyperthyroidism in Graves’ Disease, J Immunol, 2011. DOI: https://doi.org/10.4049/jimmunol.0904135

Cosmi L., Maggi L., Santarlasci V., Liotta F., Annunziato F., T helper cells plasticity in inflammation, Cytometry A, 2014, 85(1), 36-42. DOI: https://doi.org/10.1002/cyto.a.22348

Bahn R. S., Pathophysiology of Graves’ Ophthalmopathy: The Cycle of Disease, J Clin Endocrinol Metab, 2003, 88(5), 1939-1946. DOI: https://doi.org/10.1210/jc.2002-030010

Yang D., Hiromatsu Y., Hoshino T., Inoue Y., Itoh K., Nonaka K., Dominant infiltration of T(H)1-type CD4+ T cells at the retrobulbar space of patients with thyroid-associated ophthalmopathy, Thyroid, 1999, 9(3), 305-310. DOI: https://doi.org/10.1089/thy.1999.9.305

Esfahanian F., Naimi E., Doroodgar F., Jadali Z., Th1/Th2 cytokines in patients with Graves' disease with or without ophthalmopathy, Iran J Allergy Asthma Immunol, 2013, 12(2), 168-175.

Cao H. J., Wang H. S., Zhang Y., Lin H. Y., Phipps R. P., Smith T. J., Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy, J Biol Chem, 1998, 273(45), 29615-29625. DOI: https://doi.org/10.1074/jbc.273.45.29615

Smith T. J., Wang H., Evans C. H., Leukoregulin is a potent inducer of hyaluronan synthesis in cultured human orbital fibroblasts, Am J Physiol, 1995, 268(2), C382-C388. DOI: https://doi.org/10.1152/ajpcell.1995.268.2.C382

Glick A. B., Wodzinski A., Fu P., Levine A. D., Wald D. N., Impairment of regulatory T-cell function in autoimmune thyroid disease, Thyroid, 2013, 23(7), 871-878. DOI: https://doi.org/10.1089/thy.2012.0514

Klatka M., Kaszubowska L., Grywalska E., Wasiak M., Szewczyk L., Foerster J., Cyman M., Rolinski J., Treatment of Graves’ disease with methimazole in children alters the proliferation of Treg cells and CD3+ T lymphocytes, Folia Histochem Cytobiol, 2014, 52(1), 69-77. DOI: https://doi.org/10.5603/FHC.2014.0008

Crisp M. S., Lane C., Halliwell M., Wynford-Thomas D., Ludgate M., Thyrotropin receptor transcripts in human adipose tissue, J Clin Endocrinol Metab, 1997, 82(6), 2003-2005. DOI: https://doi.org/10.1210/jcem.82.6.2003

Feliciello A., Porcellini A., Ciullo I., Bonavolonta G., Avvedimento E. V., Fenzi G., Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue, Lancet, 1993, 342(8867), 337-338. DOI: https://doi.org/10.1016/0140-6736(93)91475-2

Gerding M. N., van der Meer J. W., Broenink M., Bakker O., Wiersinga W. M., Prummel M. F., Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy, Clin Endocrinol (Oxf), 2000, 52(3), 267-271. DOI: https://doi.org/10.1046/j.1365-2265.2000.00959.x

Kumar S., Coenen M. J., Scherer P. E., Bahn R. S., Evidence for Enhanced Adipogenesis in the Orbits of Patients with Graves’ Ophthalmopathy, J Clin Endocrinol Metab, 2004, 89(2), 930-935. DOI: https://doi.org/10.1210/jc.2003-031427

Kumar S., Nadeem S., Stan M. N., Coenen M., Bahn R. S., A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy, J Mol Endocrinol, 2011, 46(3), 155-163. DOI: https://doi.org/10.1530/JME-11-0006

Virakul S., van Steensel L., Dalm V. A. S. H., Paridaens D., van Hagen P. M., Dik W. A., Platelet-derived growth factor: a key factor in the pathogenesis of graves' ophthalmopathy and potential target for treatment, Eur Thyroid J, 2014, 3(4), 217-226. DOI: https://doi.org/10.1159/000367968

Haraguchi K., Shimura H., Ikeda M., Endo T., Onaya T., Effects of cytokines on expression of thyrotropin receptor mRNA in rat preadipocytes, Thyroid, 1998, 8(8), 687-692. DOI: https://doi.org/10.1089/thy.1998.8.687

Valyasevi R. W., Jyonouchi S. C., Dutton C. M., Munsakul N., Bahn R. S., Effect of Tumor Necrosis Factor-α, Interferon-γ, and Transforming Growth Factor-β on Adipogenesis and Expression of Thyrotropin Receptor in Human Orbital Preadipocyte Fibroblasts1, J Clin] Endocrinol Metab, 2001, 86(2), 903-908. DOI: https://doi.org/10.1210/jcem.86.2.7188

Tsui S., Naik V., Hoa N., Hwang C. J., Afifiyan N. F., Hikim A. S., Gianoukakis A. G., Douglas R. S., Smith T. J., Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease, J Immunol, 2008, 181(6), 4397-4405.

Dik W. A., Virakul S., van Steensel L., Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy, Exp Eye Res, 2016, 142, 83-91. DOI: https://doi.org/10.1016/j.exer.2015.02.007

Pritchard J., Han R., Horst N., Cruikshank W. W., Smith T. J., Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway, J Immunol, 2003, 170(12), 6348-6354. DOI: https://doi.org/10.4049/jimmunol.170.12.6348

Smith T. J., Kahaly G. J., Ezra D. G., Fleming J. C., Dailey R. A., Tang R. A., Harris G. J., Antonelli A., Salvi M., Goldberg R. A., Gigantelli J. W., Couch S. M., Shriver E. M., Hayek B. R., Hink E. M., Woodward R. M., Gabriel K., Magni G., Douglas R. S., Teprotumumab for Thyroid-Associated Ophthalmopathy, N Engl J Med, 2017, 376(18), 1748-1761. DOI: https://doi.org/10.1056/NEJMoa1614949

Chen H., Mester T., Raychaudhuri N., Kauh C. Y., Gupta S., Smith T. J., Douglas R. S., Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes, J Clin Endocrinol Metab, 2014, 99(9), E1635-1640. DOI: https://doi.org/10.1210/jc.2014-1580

Kang S., Sa H.-S., Current trends in the management of thyroid ophthalmopathy, Hanyang Medical Reviews, 2016, 36(3), 186-191. DOI: https://doi.org/10.7599/hmr.2016.36.3.186

Tsui S., Naik V., Hoa N., Hwang C. J., Afifiyan N. F., Sinha Hikim A., Gianoukakis A. G., Douglas R. S., Smith T. J., Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease, J Immunol, 2008, 181(6), 4397-4405. DOI: https://doi.org/10.4049/jimmunol.181.6.4397

Tramontano D., Cushing G. W., Moses A. C., Ingbar S. H., Insulinlike growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves'-IgG, Endocrinology, 1986, 119(2), 940-942. DOI: https://doi.org/10.1210/endo-119-2-940

Place R. F., Krieger C. C., Neumann S., Gershengorn M. C., Inhibiting thyrotropin/insulin-like growth factor 1 receptor crosstalk to treat Graves' ophthalmopathy: studies in orbital fibroblasts in vitro, Br J Pharmacol, 2017, 174(4), 328-340. DOI: https://doi.org/10.1111/bph.13693

Smith T. J., Tsai C. C., Shih M.-J., Tsui S., Chen B., Han R., Naik V., King C. S., Press C., Kamat S., Goldberg R. A., Phipps R. P., Douglas R. S., Gianoukakis A. G., Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy, Thyroid, 2008, 18(9), 983-988. DOI: https://doi.org/10.1089/thy.2007.0404

Smith T. J., Bahn R. S., Gorman C. A., Cheavens M., Stimulation of glycosaminoglycan accumulation by interferon gamma in cultured human retroocular fibroblasts, J Clin Endocrinol Metab, 1991, 72(5), 1169-1171. DOI: https://doi.org/10.1210/jcem-72-5-1169

Sempowski G. D., Rozenblit J., Smith T. J., Phipps R. P., Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production, Am J Physiol, 1998, 274(3), C707- C714. DOI: https://doi.org/10.1152/ajpcell.1998.274.3.C707

Khoo T. K., Coenen M. J., Schiefer A. R., Kumar S., Bahn R. S., Evidence for enhanced Thy-1 (CD90) expression in orbital fibroblasts of patients with Graves' ophthalmopathy, Thyroid, 2008, 18(12), 1291-1296. DOI: https://doi.org/10.1089/thy.2008.0255

Wang Y., Smith T. J., Current Concepts in the Molecular Pathogenesis of Thyroid-Associated Ophthalmopathy, Invest Ophthalmol Vis Sci, 2014, 55(3), 1735-1748. DOI: https://doi.org/10.1167/iovs.14-14002

Smith T. J., Koumas L., Gagnon A., Bell A., Sempowski G. D., Phipps R. P., Sorisky A., Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy, J Clin Endocrinol Metab, 2002, 87(1), 385-392. DOI: https://doi.org/10.1210/jcem.87.1.8164

Kumar S., Iyer S., Bauer H., Coenen M., Bahn R. S., A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody, J Clin Endocrinol Metab, 2012, 97(5), 1681-1687. DOI: https://doi.org/10.1210/jc.2011-2890

Guo N., Baglole C. J., O'Loughlin C. W., Feldon S. E., Phipps R. P., Mast cell-derived prostaglandin D2 controls hyaluronan synthesis in human orbital fibroblasts via DP1 activation: implications for thyroid eye disease, J Biol Chem, 2010, 285(21), 15794-15804. DOI: https://doi.org/10.1074/jbc.M109.074534

Smith T. J., Hoa N., Immunoglobulins from Patients with Graves’ Disease Induce Hyaluronan Synthesis in Their Orbital Fibroblasts through the Self-Antigen, Insulin-Like Growth Factor-I Receptor, J Clin Endocrinol Metab, 2004, 89(10), 5076-5080 DOI: https://doi.org/10.1210/jc.2004-0716

Anna Król

dominika.lacheta@wum.edu.pl

Affiliation:

Studenckie Koło Naukowe „Farmakon” przy Katedrze Biochemii i Chemii Klinicznej, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej, Warszawski Uniwersytet Medyczny, ul. Banacha 1, 02-097 Warszawa Poland

Bio Statement (e.g., department and rank)

autorka korespondująca, tel: +48 608 661 094, e-mail: dominika.lacheta@wum.edu.pl